Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms

Myeloproliferative neoplasms (MPNs) often carry JAK2(V617F), MPL(W515L), or CALR(del52) mutations. Current treatment options for MPNs include cytoreduction by hydroxyurea and JAK1/2 inhibition by ruxolitinib, both of which are not curative. We show here that cell lines expressing JAK2(V617F), MPL(W5...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood
Autores principales: Nieborowska-Skorska, Margaret, Maifrede, Silvia, Dasgupta, Yashodhara, Sullivan, Katherine, Flis, Sylwia, Le, Bac Viet, Solecka, Martyna, Belyaeva, Elizaveta A., Kubovcakova, Lucia, Nawrocki, Morgan, Kirschner, Martin, Zhao, Huaqing, Prchal, Josef T., Piwocka, Katarzyna, Moliterno, Alison R., Wasik, Mariusz, Koschmieder, Steffen, Green, Tony R., Skoda, Radek C., Skorski, Tomasz
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2017
Materias:
Myeloid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5746670/
https://ncbi.nlm.nih.gov/pubmed/29042365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-784942
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares